Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DME8273)

• Drug Name: 22R-hydroxycholesterol Drug Info
• Synonyms: 22beta-hydroxycholesterol; 22R-OHC

Indication

Disease Entry	ICD 11	Status	REF
Discovery agent	N.A.	Investigative	[1]

• Cross-matching ID:
  PubChem CID: 167685
  ChEBI ID: CHEBI:67237
  CAS Number: CAS 17954-98-2
  TTD Drug ID: DME8273

Molecule-Related Drug Atlas

Drug(s) Targeting Oxysterols receptor LXR-beta (NR1H2)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
VTB-38543	DMNY3J0	Atopic dermatitis	EA80	Phase 2	[4]
2-Propanol, Isopropanol	DML5O0H	Discovery agent	N.A.	Investigative	[5]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[6]
L-783483	DM6OTGE	Discovery agent	N.A.	Investigative	[7]
WAY-214950	DM8ODI7	Discovery agent	N.A.	Investigative	[8]
27-hydroxycholesterol	DM2L6OZ	Discovery agent	N.A.	Investigative	[9]
GSK-9772	DM4WS3R	Discovery agent	N.A.	Investigative	[10]
Riccardin C	DM6MYGX	Discovery agent	N.A.	Investigative	[11]
2-benzyl-4,5,6,7-tetrachloroisoindoline-1,3-dione	DMH76SO	Discovery agent	N.A.	Investigative	[12]
AZ12260493	DMQ5H2V	Discovery agent	N.A.	Investigative	[13]

Drug(s) Targeting Farnesoid X-activated receptor (FXR)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Chenodiol	DMQ8JIK	Cholelithiasis	DC11	Approved	[14]
Guggulsterone	DMP7LK1	Osteoarthritis	FA00-FA05	Approved	[15]
obeticholic acid	DM3Q1SM	Primary biliary cholangitis	DB96.1	Approved	[16]
GS-9674	DM936V7	Primary sclerosing cholangitis	DB96.2	Phase 3	[17]
Apomine	DM6B9HP	Osteopetrosis	LD24.10	Phase 2	[18]
LJN452	DM3XRUH	Primary biliary cholangitis	DB96.1	Phase 2	[19]
EYP001	DM5PBLM	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[20]
EDP-305	DMGJYZ8	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[21]
LMB763	DMQOXNL	Diabetic nephropathy	GB61.Z	Phase 2	[22]
MET409	DM89QXT	Non-alcoholic steatohepatitis	DB92.1	Phase 2	[23]

Drug(s) Targeting Oxysterols receptor LXR-alpha (NR1H3)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
US9073931, E2	DMK9FJG	N. A.	N. A.	Patented	[24]
BDBM50177019	DMEL28G	N. A.	N. A.	Patented	[25]
US9006244, E2b	DMP0TBO	N. A.	N. A.	Patented	[26]
US9073931, E1	DM2Z43I	N. A.	N. A.	Patented	[24]
US9006244, E1	DMBF1C0	N. A.	N. A.	Patented	[26]
BDBM50177012	DM52IQF	N. A.	N. A.	Patented	[25]
US9006244, E2a	DMPDF9B	N. A.	N. A.	Patented	[26]
67S	DMJL1MB	N. A.	N. A.	Patented	[25]
US9073931, E3	DMCYM8P	N. A.	N. A.	Patented	[24]
desmosterol	DMV8SUM	Discovery agent	N.A.	Investigative	[6]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Farnesoid X-activated receptor (FXR)	TTS4UGC	NR1H4_HUMAN	Agonist	[2]
Oxysterols receptor LXR-alpha (NR1H3)	TTECBXN	NR1H3_HUMAN	Agonist	[3]
Oxysterols receptor LXR-beta (NR1H2)	TTXA6PH	NR1H2_HUMAN	Agonist	[3]

References

• [1] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2742).
• [2] Oxysterol 22(R)-hydroxycholesterol induces the expression of the bile salt export pump through nuclear receptor farsenoid X receptor but not liver ... J Pharmacol Exp Ther. 2006 Apr;317(1):317-25.
• [3] An oxysterol signalling pathway mediated by the nuclear receptor LXR alpha. Nature. 1996 Oct 24;383(6602):728-31.
• [4] Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
• [5] How many drug targets are there Nat Rev Drug Discov. 2006 Dec;5(12):993-6.
• [6] Sterol intermediates from cholesterol biosynthetic pathway as liver X receptor ligands. J Biol Chem. 2006 Sep 22;281(38):27816-26.
• [7] A novel liver X receptor agonist establishes species differences in the regulation of cholesterol 7alpha-hydroxylase (CYP7a). Endocrinology. 2002 Jul;143(7):2548-58.
• [8] Indazole-based liver X receptor (LXR) modulators with maintained atherosclerotic lesion reduction activity but diminished stimulation of hepatic tr... J Med Chem. 2008 Nov 27;51(22):7161-8.
• [9] 27-hydroxycholesterol is an endogenous ligand for liver X receptor in cholesterol-loaded cells. J Biol Chem. 2001 Oct 19;276(42):38378-87.
• [10] Structure-guided design of N-phenyl tertiary amines as transrepression-selective liver X receptor modulators with anti-inflammatory activity. J Med Chem. 2008 Sep 25;51(18):5758-65.
• [11] Co-existence of alpha-glucosidase-inhibitory and liver X receptor-regulatory activities and their separation by structural development. Bioorg Med Chem. 2008 Apr 15;16(8):4272-85.
• [12] Liver X receptor antagonists with a phthalimide skeleton derived from thalidomide-related glucosidase inhibitors. Bioorg Med Chem Lett. 2007 Jul 15;17(14):3957-61.
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 601).
• [14] Lithocholic acid decreases expression of bile salt export pump through farnesoid X receptor antagonist activity. J Biol Chem. 2002 Aug 30;277(35):31441-7.
• [15] Effect of guggulsterone and cembranoids of Commiphora mukul on pancreatic phospholipase A(2): role in hypocholesterolemia. J Nat Prod. 2009 Jan;72(1):24-8.
• [16] 2016 FDA drug approvals. Nat Rev Drug Discov. 2017 Feb 2;16(2):73-76.
• [17] The Nonsteroidal Farnesoid X Receptor Agonist Cilofexor (GS-9674) Improves Markers of Cholestasis and Liver Injury in Patients With Primary Sclerosing Cholangitis. Hepatology. 2019 Sep;70(3):788-801.
• [18] The nuclear receptors FXR and LXRalpha: potential targets for the development of drugs affecting lipid metabolism and neoplastic diseases. Curr Pharm Des. 2001 Mar;7(4):231-59.
• [19] FXR modulators for enterohepatic and metabolic diseases.Expert Opin Ther Pat. 2018 Nov;28(11):765-782.
• [20] Clinical pipeline report, company report or official report of ENYO Pharma.
• [21] A novel non-bile acid FXR agonist EDP-305 potently suppresses liver injury and fibrosis without worsening of ductular reaction. Liver Int. 2020 Jul;40(7):1655-1669.
• [22] Nidufexor (LMB763), a Novel FXR Modulator for the Treatment of Nonalcoholic Steatohepatitis. J Med Chem. 2020 Apr 23;63(8):3868-3880.
• [23] Clinical pipeline report, company report or official report of Metacrine.
• [24] Liver X receptor modulators. US9073931.
• [25] Piperazine derivatives as liver X receptor modulators. US10144715.
• [26] Liver X receptor modulators. US9006244.